Lexeo Therapeutics (NASDAQ:LXEO) CFO Louis Edward Tamayo Sells 4,641 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CFO Louis Edward Tamayo sold 4,641 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.49, for a total value of $20,838.09. Following the completion of the transaction, the chief financial officer owned 97,024 shares of the company’s stock, valued at $435,637.76. The trade was a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lexeo Therapeutics Trading Down 4.5%

NASDAQ LXEO opened at $4.45 on Thursday. The business’s 50-day moving average price is $5.12 and its 200 day moving average price is $6.63. Lexeo Therapeutics, Inc. has a twelve month low of $3.60 and a twelve month high of $10.99. The company has a market capitalization of $349.41 million, a PE ratio of -3.07 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Equities analysts predict that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LXEO. Mirae Asset Global Investments Co. Ltd. grew its stake in Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after buying an additional 1,459 shares during the period. Bank of America Corp DE raised its stake in shares of Lexeo Therapeutics by 6.1% in the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after acquiring an additional 1,626 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Lexeo Therapeutics by 123.7% during the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after acquiring an additional 2,148 shares in the last quarter. Intech Investment Management LLC boosted its position in Lexeo Therapeutics by 19.5% during the 4th quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after purchasing an additional 2,317 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in Lexeo Therapeutics by 25.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,893 shares of the company’s stock worth $118,000 after purchasing an additional 2,427 shares during the period. 60.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Weiss Ratings lowered shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 25th. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. dropped their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.